AGIO · XBRL financial data

Agios Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AGIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	7	7*	8	9	9	11*	9	12	13	20*	21	45
Cost of goods and services sold	1	1*	1	1	1	1*	1	2	2	2*	1	3
Research and development	82	77*	69	77	72	83*	73	92	87	88*	81	101
Selling, general and administrative	26	35*	31	36	39	52*	42	46	41	52*	48	52
Operating income (loss)	(101)	(106)*	(92)	(106)	(103)	(125)*	(107)	(127)	(117)	(122)*	(110)	(111)
Other income (expense)	1	2*	2	2	2	2*	1	1	0	0*	0	0
Income tax expense (benefit)	0	0*	—	—	53	(9)*	—	—	0	(1)*	—	—
Net income (loss)	(91)	(96)*	(82)	(96)	948	(97)*	(89)	(112)	(103)	(108)*	(99)	(101)
Earnings per share, basic USD per share	(1.64)	(1.72)*	(1.45)	(1.69)	16.65	(1.69)*	(1.55)	(1.93)	(1.78)	(1.85)*	(1.69)	(1.69)
Earnings per share, diluted USD per share	(1.64)	(1.72)*	(1.45)	(1.69)	16.22	(1.61)*	(1.55)	(1.93)	(1.78)	(1.85)*	(1.69)	(1.69)
Weighted average shares, basic millions of shares	56	56*	56	57	57	57*	57	58	58	58*	59	59
Weighted average shares, diluted millions of shares	56	56*	56	57	58	60*	57	58	58	58*	59	59

Fiscal quarters (AGIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	64	88	119	85	254	76	79	81	93	89	114	100
Marketable securities	583	689	479	485	751	817	814	858	860	765	623	518
Marketable securities, non-current	225	29	116	75	656	638	531	400	304	310	308	347
Inventory	17	19	23	24	26	28	30	31	32	33	35	36
Prepaid and other current assets	38	35	39	35	40	40	42	45	43	44	47	46
Total current assets	704	834	664	632	1,074	966	969	1,019	1,033	942	835	718
Property and equipment, net	17	15	14	13	12	12	11	11	11	11	11	10
Right-of-use asset	57	54	52	49	46	43	40	37	34	30	27	24
Total assets	1,007	937	850	773	1,792	1,663	1,556	1,471	1,386	1,297	1,185	1,108
Accounts payable	13	10	11	10	17	17	14	18	20	18	14	16
Accrued liabilities	30	43	25	37	33	47	21	35	37	45	26	35
Total current liabilities	58	68	52	63	119	81	52	70	75	82	59	70
Lease liability, non-current	61	57	53	49	45	40	36	31	27	22	17	12
Total liabilities	120	126	106	113	165	122	89	102	101	104	76	82
Accumulated deficit	(727)	(823)	(904)	(1,000)	(52)	(149)	(238)	(350)	(454)	(562)	(661)	(762)
Total stockholders' equity	887	811	744	661	1,627	1,541	1,467	1,370	1,284	1,193	1,109	1,026
Total liabilities and equity	1,007	937	850	773	1,792	1,663	1,556	1,471	1,386	1,297	1,185	1,108
Common shares outstanding (cover page) millions of shares	56	56	57	57	57	57	58	58	58	59	59	60

Fiscal quarters (AGIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(91)	(96)*	(82)	(96)	948	(97)*	(89)	(112)	(103)	(108)*	(99)	(101)
Stock-based compensation	9*	14*	9	12*	11*	11*	11	15*	12*	14*	16	16*
Net cash from operating activities	(62)*	(72)*	(100)	(73)*	(84)*	(133)*	(111)	(77)*	(88)*	(96)*	(119)	(57)*
Purchases of property and equipment	0*	0*	0	0*	0*	1*	1	1*	2*	1*	1	1*
Net cash from investing activities	39*	96*	125	37*	251*	(49)*	113	79*	96*	90*	141	40*
Net cash from financing activities	2*	1*	6	1*	3*	5*	2	0*	4*	3*	2	3*
Net change in cash	(20)*	24*	31	(34)*	169*	(177)*	3	2*	12*	(4)*	24	(14)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2.8	45	1.9*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.